Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn

2. Roivant Sciences Ltd. (NASDAQ:ROIV)

Greenlight Capital’s Equity Stakes: $62.36 Million

Number of Hedge Fund Holders: 44

Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage biopharmaceutical company developing and commercializing medicines for inflammation and immunology. It also provides Vants a model to develop and commercialize its drugs and technologies, focusing on biopharmaceutical businesses.

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the top healthcare stocks in David Einhorn’s portfolio, making significant progress in expanding its clinical pipeline. The company has made significant progress on the development of brepocitinib for cutaneous sarcoidosis as it also works on trials for IMVT-1402 and batoclimab across multiple indications.

Roivant Sciences Ltd. (NASDAQ:ROIV) maintains a strong financial standing to progress its clinical program, supported by a cash reserve of approximately $5.2 billion as of December 31, 2024. The company plans to capitalize on its robust cash reserves to enhance innovation and expand its pipeline. It also plans to achieve several critical study outcomes throughout 2025, which could significantly influence its future growth trajectory. With a number of important trials in progress, including IMVT-1402 for Graves’ disease and rheumatoid arthritis and brepocitinib for dermatomyositis, Roivant is strategically pursuing its clinical agenda.